Accessibility Menu
 

Island Pharmaceuticals

(ASX) ILA

Current Price$0.37
Market Cap$99.55M
Since IPO (2021)-25%
5 YearN/A
1 Year+111%
1 Month-24%

Island Pharmaceuticals Financials at a Glance

Market Cap

$99.55M

Revenue (TTM)

$421.43K

Net Income (TTM)

$10.44M

EPS (TTM)

$-0.03

P/E Ratio

-11.97

Dividend

$0.00

Beta (Volatility)

0.12 (Low)

Price

$0.37

Volume

53,659

Open

$0.38

Previous Close

$0.37

Daily Range

$0.37 - $0.38

52-Week Range

$0.12 - $0.63

ILA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Island Pharmaceuticals

Industry

Pharmaceuticals

CEO

David Foster, PhD

Headquarters

Camberwell, VIC 3124, AU

ILA Financials

Key Financial Metrics (TTM)

Gross Margin

-33%

Operating Margin

-367%

Net Income Margin

-326%

Return on Equity

-130%

Return on Capital

-1%

Return on Assets

-90%

Earnings Yield

-8.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$99.55M

Shares Outstanding

269.05M

Volume

53.66K

Short Interest

0.00%

Avg. Volume

339.81K

Financials (TTM)

Gross Profit

$1.29M

Operating Income

$5.36M

EBITDA

$0.00

Operating Cash Flow

$2.77M

Capital Expenditure

$5.00

Free Cash Flow

$2.77M

Cash & ST Invst.

$7.25M

Total Debt

$0.00

Island Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$52.65K

+83.6%

Gross Margin

0.00%

N/A

Market Cap

$99.55M

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

$4.81M

-316.5%

EBITDA

$4.90M

-484.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$6.87M

+1367.2%

Accounts Receivable

$192.40K

-69.5%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-89.78%

N/A

Return on Invested Capital

-1.13%

N/A

Free Cash Flow

$1.98M

-46.2%

Operating Cash Flow

$1.98M

-46.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATH.AXAlterity Therapeutics Limited
$0.01+0.00%
ALA.AXArovella Therapeutics Limited
$0.09+29.17%
ATX.AXAmplia Therapeutics Limited
$0.15+0.00%
BIO.AXBiome Australia Limited
$0.34+2.99%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$61.70+0.05%
NOKNokia
$9.54+0.01%
NVDANvidia
$183.89+0.01%
NIONio
$6.08-0.05%

Questions About ILA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.